Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells
Citations
719 citations
251 citations
83 citations
61 citations
51 citations
References
10,602 citations
"Atezolizumab potentiates Tcell-medi..." refers background in this paper
...Immune checkpoints are a set of inhibitory pathways in the immune system that are required for maintaining self-tolerance and preventing host tissue damage by regulating durability of immune response.(7) Programmed cell death ligand 1 (PD-L1), a key immune checkpointmolecule andmember of B7 transmembrane protein family, interacts with its receptor, programmed cell death (PD-1), and induces negative regulatory signal by neutralizing cytotoxic T cell activity....
[...]
4,290 citations
"Atezolizumab potentiates Tcell-medi..." refers background in this paper
...Programmed cell death ligand 1 (PD-L1), a key immune checkpointmolecule andmember of B7 transmembrane protein family, interacts with its receptor, programmed cell death (PD-1), and induces negative regulatory signal by neutralizing cytotoxic T cell activity.(8) Early preclinical studies have shown that disrupting PD-L1/PD-1 association by using monoclonal antibodies may enhance anti-tumor immunity and promote tumor regression in in vitro and in vivo models....
[...]
4,227 citations
"Atezolizumab potentiates Tcell-medi..." refers background in this paper
...ATE, which selectively targets PD-L1 and inhibit binding of PD-L1 to receptor PD-1, showed improved clinical utility against urothelial and non-small cell lung carcinomas, and later received market approval for such patient populations.16,17 ATE, formerly known as MPDL3280A, was isolated from a single phage clone by screening human phage display library directed against extracellular domain-Fc fusion of human PD-L1....
[...]
...ATE, formerly known as MPDL3280A, was isolated from a single phage clone by screening human phage display library directed against extracellular domain-Fc fusion of human PD-L1.(18) Although clinical activity of ATE is explored in variety of cancer types, more recently, a phase 3 clinical trial using ATE with nabpaclitaxel in patients with locally advanced or metastatic TNBC patients showed significantly longer progression-free survival compared with placebo-nab-paclitaxel treated group....
[...]
...Previous study has shown that proteasomal inhibitor MG132 can increase PD-L1 expression in prostate cancer cells by blocking its degradation,24 hence we hypothesized that combining ATE with proteasomal and lysosomal inhibitors in immune-dependent cytotoxicity assays can further increase efficacy of ATE against TNBC cells by preventing proteasomal or lysosomal-mediated degradation of PD-L1....
[...]
4,215 citations
"Atezolizumab potentiates Tcell-medi..." refers background in this paper
...Triple negative breast cancer (TNBC), which represents about 10–20% of all mammary tumors, is characterized by lack of molecular therapeutic targets like estrogen receptor (ER), progesterone receptor (PR) and HER2.(1,2) TNBCs are highly aggressive tumors with dismal prognosis....
[...]
...Triple negative breast cancer (TNBC), which represents about 10–20% of all mammary tumors, is characterized by lack of molecular therapeutic targets like estrogen receptor (ER), progesterone receptor (PR) and HER2....
[...]
3,496 citations
"Atezolizumab potentiates Tcell-medi..." refers background in this paper
...ATE, which selectively targets PD-L1 and inhibit binding of PD-L1 to receptor PD-1, showed improved clinical utility against urothelial and non-small cell lung carcinomas, and later received market approval for such patient populations.(16,17) ATE, formerly known as MPDL3280A, was isolated from a single phage clone by screening human phage display library directed against extracellular domain-Fc fusion of human PD-L1....
[...]